Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Other Non-Current Liabilities (2021 - 2024)

Historic Other Non-Current Liabilities for Relay Therapeutics (RLAY) over the last 4 years, with Q1 2024 value amounting to $11.4 million.

  • Relay Therapeutics' Other Non-Current Liabilities fell 6374.82% to $11.4 million in Q1 2024 from the same period last year, while for Mar 2024 it was $11.4 million, marking a year-over-year decrease of 6374.82%. This contributed to the annual value of $13.2 million for FY2023, which is 5921.3% down from last year.
  • As of Q1 2024, Relay Therapeutics' Other Non-Current Liabilities stood at $11.4 million, which was down 6374.82% from $13.2 million recorded in Q4 2023.
  • Relay Therapeutics' 5-year Other Non-Current Liabilities high stood at $50.5 million for Q3 2021, and its period low was $11.4 million during Q1 2024.
  • Its 4-year average for Other Non-Current Liabilities is $35.8 million, with a median of $37.6 million in 2022.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first crashed by 536.88% in 2022, then crashed by 6374.82% in 2024.
  • Over the past 4 years, Relay Therapeutics' Other Non-Current Liabilities (Quarter) stood at $50.3 million in 2021, then tumbled by 35.58% to $32.4 million in 2022, then tumbled by 59.21% to $13.2 million in 2023, then decreased by 13.87% to $11.4 million in 2024.
  • Its Other Non-Current Liabilities stands at $11.4 million for Q1 2024, versus $13.2 million for Q4 2023 and $28.0 million for Q3 2023.